Physician profile
Helen L Baron
NPI 1295762995
$957,578.28
in general payments reported to CMS, 2019-2025
18 companies · $141K in 2025
The $141K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305K · 2020: $119K · 2021: $112K · 2022: $122K · 2023: $112K · 2024: $48K · 2025: $141K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $139K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $102K · Travel and Lodging: $36K · Consulting Fee: $19K · Food and Beverage: $4,607 · Education: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $138,840.94 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $102,277.75 |
| Travel and Lodging | $35,971.54 |
| Consulting Fee | $18,761.25 |
| Food and Beverage | $4,607.33 |
| Education | $419.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $345,154.44 | 2019-2025 | |
| Novo Nordisk INC | $316,686.72 | 2019-2025 | Ozempic, Rybelsus, Victoza |
| Dexcom, INC. | $107,654.70 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals Lp | $85,762.83 | 2019-2022 | |
| Abbott Laboratories | $49,492.61 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $26,481.00 | 2021-2023 | |
| Lilly USA, LLC | $13,426.94 | 2022-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11,916.25 | 2023-2025 | Jardiance |
| Beta Bionics, INC. | $635.78 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tandem Diabetes Care, INC. | $106.46 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $86.51 | 2021-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $36.68 | 2019 | |
| Radius Health, INC. | $29.91 | 2024 | Tymlos |
| Cequr Corporation | $26.44 | 2023-2025 | Cequr Simplicity |
| Janssen Pharmaceuticals, INC | $22.60 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Companion Medical, INC. | $20.91 | 2019 | |
| Mannkind Corporation | $18.75 | 2019 | |
| Medtronic, INC. | $18.75 | 2025 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Baron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.